A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

NCT00502112 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: lintuzumab
DRUG: lenalidomide

Sponsor

Seagen Inc.